Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Reference: Tucatinib with Trastuzumab and Pertuzumab for HER2-Positive Metastatic Breast Cancer
The HER2CLIMB-05 phase III trial demonstrated that adding tucatinib to trastuzumab and pertuzumab as first-line maintenance therapy significantly improved progression-free survival
New Protocol: Neoadjuvant Endocrine Therapy with Trastuzumab and Pertuzumab for Triple-Positive Breast Cancer
The WSG TP-II randomized phase II trial showed that neoadjuvant endocrine therapy plus trastuzumab and pertuzumab results in lower pathologic complete response rates than paclitaxe
New Reference: Teclistamab for Relapsed / Refractory Multiple Myeloma
In this phase 3 trial, teclistamab monotherapy significantly improved progression-free and overall survival compared with pomalidomide-based or carfilzomib-based regimens in patien
New Reference: Tebentafusp for Metastatic Uveal Melanoma
This phase 3 trial demonstrated that tebentafusp significantly improved overall survival compared with investigator's choice in previously untreated HLA-A*02:01-positive metastatic
New Reference: Talazoparib with Enzalutamide in HRR-Altered Metastatic Prostate Cancer
This phase 3 randomized trial demonstrated that talazoparib plus enzalutamide significantly improved imaging-based progression-free survival compared with placebo plus enzalutamide
New Protocol: Tafasitamab – Lenalidomide with R-CHOP for High-Risk Large B Cell Lymphoma
In this phase 3 trial involving patients with high-risk diffuse large B-cell lymphoma, addition of tafasitamab and lenalidomide to R-CHOP significantly improved progression-free su
New Indication: Adjuvant Selpercatinib in RET-Fusion Positive NSCLC
In this phase 3 trial of patients with early-stage RET fusion-positive NSCLC, adjuvant selpercatinib significantly improved 2-year event-free survival compared to placebo, reducing
New Indication: Sunvozertinib for Untreated Advanced NSCLC with EGFR Exon 20 Insertions
In this international phase 3 trial, first-line sunvozertinib significantly improved progression-free survival and objective response rate compared to carboplatin-pemetrexed chemot
New Reference: Lorlatinib for ALK+ NSCLC
This 7-year update of the CROWN trial demonstrated that lorlatinib maintained unprecedented long-term progression-free survival benefit compared to crizotinib in advanced ALK-posit
